Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors

A c-Met inhibitor tivantinib is a candidate anticancer agent for patients with hepatocellular carcinoma (HCC), and CYP2C19 is the key metabolic enzyme for tivantinib. Previous Japanese phase I studies in patients with solid tumors (except HCC) recommend 360 mg twice daily (BID) and 240 mg BID for CY...

Descripción completa

Detalles Bibliográficos
Autores principales: Okusaka, Takuji, Aramaki, Takeshi, Inaba, Yoshitaka, Nakamura, Shinichiro, Morimoto, Manabu, Moriguchi, Michihisa, Sato, Takashi, Ikawa, Yuta, Ikeda, Masafumi, Furuse, Junji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BlackWell Publishing Ltd 2015
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452163/
https://www.ncbi.nlm.nih.gov/pubmed/25711511
http://dx.doi.org/10.1111/cas.12644

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4452163/
https://www.ncbi.nlm.nih.gov/pubmed/25711511
http://dx.doi.org/10.1111/cas.12644

Ejemplares similares